The psychedelic medicine industry has a new player. Albert Labs began trading today on the Canadian Securities Exchange (“CSE”) under the ticker symbol “ABRT”.

According to the company, “Albert Labs is a laboratory-based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies through accelerated regulatory approval pathways” and the “first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.”

Click here for a look at their clinical research and focus on Real World Evidence Studies.

And here’s an exclusive quote from their Chief Commercial Officer:

“We are in a unique position and mitigated excessive risk of our capital by going down the Real World Evidence route. Not only is this a much faster route to provide solutions to patients but also to see results. We’re able to work with existing programs and organisations to deliver treatments in the Real-World setting. This comes at a lower cost and will help bring psychedelic assisted therapy to patients within the present health system. This strategy presents an enticing and ethical investment opportunity.” – Graeme McFarlane, Chief Commercial Officer.

For more information see their Investors Presentation here, and see below for an interview with Dr Malcolm Barratt-Johnson, Chief Medical Officer

https://youtu.be/_yMkrZgeU7k

Stay tuned to Microdose for more details on Albert Labs’ work and see the full press below. 

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading On The Canadian Securities Exchange

Accelerating access to psychedelic-based medicines for patients with urgent and unmet needs.

MARCH 10th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (the “Company”), a research and drug development company producing natural pharmaceutical-quality psilocybin medicine to treat cancer-related distress, is pleased to announce that its shares will commence trading today on the Canadian Securities Exchange (“CSE”) under the ticker symbol “ABRT”.

Transaction Summary

The Company has closed its previously announced reverse take-over transaction with ME. Resource Corp. (“MEC”) and has acquired all of the outstanding securities of MEC in exchange for the issuance of securities of the Company (the “Transaction”). Albert Labs will now pursue its business activities as described in the Company’s filing statement dated March 7, 2022 available at www.thecse.com on the trading date.

In accordance with the amended and restated arrangement, upon completion of the Transaction, the Company changed its name from “ME. Resource Corp” to “Albert Labs  International Corp.” and consolidated its issued and outstanding common shares on the basis of 10:1 (the “Consolidation”). The Company closed a debt settlement and private placement offering of 18,947,500 Albert Labs’ Shares at a price per share of $0.25 for gross proceeds of $4,736,875. Included in this financing round was significant investment from the Albert Labs’ senior management team to the sum of $2,046,660, and the balance of $2,690,215 was coordinated with support from Chrystal Capital Partners based in the UK. Albert Labs and its 67,280,035 common shares will resume trading on March 10, 2022 and will trade under its new symbol “ABRT”.

The Company intends to use the net proceeds from the public offering, together with its existing cash and cash equivalents, (i) to manufacture and deliver natural psilocybin, in the form of a prescription drug known as KRN-101 to trial centres, and (ii) for the effective conduct of Real World Evidence (RWE) trials, including all necessary partnerships, to lead to a regulatory approved medication for treating anxiety and depression, initially in cancer patients.

About Albert Labs

Through an approved, fast track clinical pathway, focusing on Real World Evidence (RWE), Albert Labs will improve patient access to psychedelic-assisted therapies, starting in Europe with the goal of receiving a marketing authorisation and creating highly successful, licensed medicines. After the successful conclusion of the first development program, Albert Labs will expand to other indications and commercialise other novel therapeutics to address the rapidly growing mental health crisis.

• Fast track development of authorised psychedelic medicine using RWE – Albert Labs is the first company using RWE studies to demonstrate psychedelic-assisted psychotherapy. Working with the largest oncology centre in Europe, Albert Labs will treat patients in 2022 while at the same time working towards a full marketing authorisation granted by health regulators.

• Access to an immediate and large addressable market – Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of 1.2 million in the UK alone, with 50,000-100,000 new sufferers annually. Expanding this to Europe and the US, the total addressable market is over 15 million people with 700,000-1 million new sufferers annually. From this initial focus Albert Labs will then address broader mental health concerns, reported to affect over a billion people worldwide.

• A low cost and risk mitigated strategy to develop pharmaceuticals – Through an RWE strategy and utilising a natural compound with a history of safety and efficacy, Albert Labs requires significantly less capital expenditure than companies developing novel molecules and/or setting up clinic operations. Randomised controlled trials (RCTs) can cost upwards of $1/2 billion and take 7-12 years. RWE offers a faster but no less rigorous process to achieve licensed medicine. This comes at lower costs yet receives the same approvals, whilst also receiving reimbursement to drive early and sustained revenues.

• IP protected and cost-effective production of psilocybin-based KRN-101 – Albert Labs focuses on natural psilocybin and uses advanced culture and natural extraction technology to produce their Active Pharmaceutical Ingredient (API). This proprietary technology will provide consistent and repeatable EU GMP psilocybin, which importantly will have other synergistic bio-actives naturally found in the mycelium.

“As Albert Labs announces the start of trading on the CSE, I am proud to be leading such a world-class team, who are pioneering a rigorous yet accelerated development of a novel mental health treatment. If the trial of our first drug candidate this summer/fall is successful, and we have every reason to believe it will be, that event is likely to be the biggest game-changer in mental health for more than 20 years. We expect expedited regulatory approvals in the UK, followed by rapid expansion to other geographies and other mental health concerns. We’re working rapidly to treat what is becoming a massively debilitating and costly global health challenge.”, Said Dr Michael Raymont, Chief Executive Officer of Albert Labs. Click here to hear more from Dr Raymont.

“The use of classical Random Controlled Trials in medicinal development can be long, costly, and may delay a patient’s access to a product. Recently published guidance by my former colleagues at the MHRA outlines the use of Real World Evidence (RWE) in support of licensing indications, which goes to validate Albert Labs’ use of an RWE based regulatory approach.” Added Dr Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs. If you wish to hear more from Dr Barratt-Johnson regarding RWE and the MHRA’s guidance click here.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs Inc.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:

Barney Neal, Chief Communications Officer at Albert Labs,

Email: press@albertlabs.com

Website: https://albertlabs.com/

Tel: +44 7828 008237